Integrative analysis of small non-coding RNAs predicts a piRNA/miRNA-CCND1/BRAF/HRH1/ATXN3 regulatory circuit that drives oncogenesis in glioblastoma

Nayak, Rojalin; Chattopadhyay, Trisha; Gupta, Pooja; Mallick, Bibekanand

doi:10.1039/d2mo00245k

Cited by 4 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Research shows that the expression of miRNAs is significantly altered in cancer and may act as tumor suppressors or oncogenes in different cancers by sequence-specific binding with cognate mRNA targets 3 0 -UTRs. [32][33][34] Dysregulation in the expression of miRNAs affects the critical steps in oncogenic processes like metastasis, [35][36][37] angiogenesis, 38 epithelial to mesenchymal transition (EMT), 39 autophagy, 40 chemosensitivity, 41,42 and so on, by altering the signaling pathways related to these processes in a target-dependent manner. This is also associated with overall patient survival and tumor recurrence.…”

Section: Introductionmentioning

confidence: 99%

“…Evidence shows that miRNA plays a crucial role in developing and progressing several diseases, like retinal disorders, cardiovascular diseases, neurodegenerative diseases, and cancer 31 . Research shows that the expression of miRNAs is significantly altered in cancer and may act as tumor suppressors or oncogenes in different cancers by sequence‐specific binding with cognate mRNA targets 3′‐UTRs 32–34 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miR‐203a—A multifaceted regulator modulating cancer hallmarks and therapy response

Biswal,

Lalruatfela,

Behera

et al. 2023

IUBMB Life

Self Cite

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of noncoding RNAs of about 19–25 nucleotides, which serve as critical modulators of various cellular and biological processes by target gene regulation. Dysregulated expression of miRNAs modulates the pathophysiology of various human diseases, including cancer. Among miRNAs, miR‐203a is one of the most extensively researched dysregulated miRNAs in different cancers. Our review investigated the roles of miR‐203a in the hallmarks of cancer modulating different pathways through target gene regulations, chemoresistance, its crosstalk with other ncRNAs or genes in terms of ceRNAs impacting oncogenesis, and its potential applications in the diagnosis, prognosis, and chemotherapeutic responses in different cancer types. miR‐203a impacts cancer cell behavior by regulating these exclusive hallmarks‐ sustaining proliferation, cell growth, invasion and metastasis, cell death, and angiogenesis. Besides, miR‐203a is found in human circulating biofluids like plasma or serum of colorectal cancer, cervical cancer, and hepatocellular carcinoma, hinting at its potential as a biomarker. Further, miR‐203a is involved in enhancing the chemosensitivity of cisplatin, docetaxel, paclitaxel, doxorubicin, and 5‐fluorouracil in a variety of malignancies through their cognate target genes. These results suggest that miR‐203a is a crucial multifaceted miRNA that controls cancer cell proliferation, metastasis, and chemotherapy response, shedding new light on its possible application.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

miR‐203a—A multifaceted regulator modulating cancer hallmarks and therapy response

Biswal,

Lalruatfela,

Behera

et al. 2023

IUBMB Life

Self Cite

View full text Add to dashboard Cite

show abstract

miR-128-3p suppresses tumor growth and enhances chemosensitivity in tongue squamous cell carcinoma through MAP2K7 targeting

Gupta,

Mallick

2024

Mol Biol Rep

View full text Add to dashboard Cite

The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma

Shirai,

Ueno,

Kojima

et al. 2024

J Neurooncol

View full text Add to dashboard Cite

Purpose Various molecular profiles are needed to classify malignant brain tumors, including gliomas, based on the latest classification criteria of the World Health Organization, and their poor prognosis necessitates new therapeutic targets. The Todai OncoPanel 2 RNA Panel (TOP2-RNA) is a custom-target RNA-sequencing (RNA-seq) using the junction capture method to maximize the sensitivity of detecting 455 fusion gene transcripts and analyze the expression profiles of 1,390 genes. This study aimed to classify gliomas and identify their molecular targets using TOP2-RNA. Methods A total of 124 frozen samples of malignant gliomas were subjected to TOP2-RNA for classification based on their molecular profiles and the identification of molecular targets. Results Among 55 glioblastoma cases, gene fusions were detected in 11 cases (20%), including novel MET fusions. Seven tyrosine kinase genes were found to be overexpressed in 15 cases (27.3%). In contrast to isocitrate dehydrogenase (IDH) wild-type glioblastoma, IDH-mutant tumors, including astrocytomas and oligodendrogliomas, barely harbor fusion genes or gene overexpression. Of the 34 overexpressed tyrosine kinase genes, MDM2 and CDK4 in glioblastoma, 22 copy number amplifications (64.7%) were observed. When comparing astrocytomas and oligodendrogliomas in gene set enrichment analysis, the gene sets related to 1p36 and 19q were highly enriched in astrocytomas, suggesting that regional genomic DNA copy number alterations can be evaluated by gene expression analysis. Conclusions TOP2-RNA is a highly sensitive assay for detecting fusion genes, exon skipping, and aberrant gene expression. Alterations in targetable driver genes were identified in more than 50% of glioblastoma. Molecular profiling by TOP2-RNA provides ample predictive, prognostic, and diagnostic biomarkers that may not be identified by conventional assays and, therefore, is expected to increase treatment options for individual patients with glioma.

show abstract

Integrative analysis of small non-coding RNAs predicts a piRNA/miRNA-CCND1/BRAF/HRH1/ATXN3 regulatory circuit that drives oncogenesis in glioblastoma

Abstract: The high-grade astrocytoma, glioblastoma multiforme (GBM), is the most common primary tumour of the brain, known for being aggressive and developing drug resistance. The non-coding RNAs (ncRNAs), such as microRNAs...

Cited by 4 publications

References 64 publications

miR‐203a—A multifaceted regulator modulating cancer hallmarks and therapy response

miR‐203a—A multifaceted regulator modulating cancer hallmarks and therapy response

miR-128-3p suppresses tumor growth and enhances chemosensitivity in tongue squamous cell carcinoma through MAP2K7 targeting

The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma

Contact Info

Product

Resources

About